Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance

Clinical Drug Investigation

Volumn 26, Issue 9, 2006, Pages 529-539

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   D'Angelo, Angela ^a   Ragonesi, Pietro D ^c   Ciccarelli, Leonardina ^a   Fogari, Elena ^a   Salvadeo, Sibilla A T ^a   Ferrari, Ilaria ^a   Gravina, Alessia ^a   Fassi, Raffaella ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; DOXAZOSIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEALTH CENTER; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; ITALY; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TITRIMETRY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ACARBOSE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DOUBLE-BLIND METHOD; DOXAZOSIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED;

EID: 33747414045     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626090-00006     Document Type: Article

References (43)

1. American Diabetes Association. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 2002; 25 (Sl): 1-147
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287 (19): 2570-81
3. Derosa G, Cicero AF, Ciccarelli L, et al. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther 2003; 25 (7): 2006-21
4. Derosa G, Cicero AFG, Bertone G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther 2004; 26 (8): 1228-36
5. Kasiske BL, Ma JZ, Kalil RSN, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122 (2): 133-41
6. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and thiazides. Am J Cardiol 1996; 77: 12b-6b
7. Schmitz G, Stumpe KO, Herrmann W, et al. Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial. Blood Press 1996; 5: 354-9
8. Krone W, Nagele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 1988; 116: 1729-34
9. Feldman R. ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X. Can J Cardiol 2000; 16 (E): 41E-4E
10. Lerch M, Teuscher AU, Beissner P, et al. Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol 1998; 31: 576-80
11. Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26 (5): 1402-7
12. Cheung R, Lewanczuk RZ, Rodger NW, et al. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int J Clin Pract 1999; 53: 584-92
13. Derosa G, Cicero AFG, Gaddi A, et al. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. J Cardiovasc Pharmacol 2005; 45 (6): 599-604
14. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7
15. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 2003; 290 (4): 486-94
16. American Diabetes Association. Screening for diabetes (position statement). Diabetes Care 2001; 24 Suppl. 1: S21-4
17. World Health Organization. International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151-83
18. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO Consultation on Obesity. Geneva: WHO, 1997 Jun
19. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 2001; 24 Suppl. 1: S44-7
20. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9
21. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin: relevance to diabetes mellitus. Science 1978; 200: 21-7
22. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-30
23. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-6
24. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. J Clin Chem Clin Biochem 1978; 15: 121-30
25. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bergmeyer HU, editor. Methods of enzymatic analysis. 2nd English ed. New York: Academic Press, 1974: 18-31
26. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-53
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
28. Winer BJ. Statistical principles in experimental design. 2nd ed. New York: McGraw-Hill, 1971
29. Rachmani R, Bar-Dayan Y, Ronen Z, et al. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study. Diabetes Obes Metab 2004; 6 (1): 63-8
30. Josse RG, Chiasson JL, Ryan EA, et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003; 59 (1): 37-42
31. Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diabetes Obes Metab 2004; 6 (5): 384-90
32. Goke B; German Pioglitazone Study Group. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 2002; 1 (5): 329-36
33. Ishimitsu T, Yagi S, Sugishita Y, et al. Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. Hypertens Res 1996; 19 (1): 43-9
34. Shionoiri H, Ashino K, Yamunaka K, et al. Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance. Clin Ther 1997; 19 (3): 527-36
35. Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press 1998; 7 (1): 39-45
36. Hirano T, Yoshino G, Kashiwazaki K, et al. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am J Hypertens 2001; 14 (9 Pt 1): 908-13
37. Kinoshita M, Shimazu N, Fujita M, et al. Doxazosin, an alpha 1-adrenergic antihypertensive agent, decreases serum oxidized LDL. Am J Hypertens 2001; 14 (3): 267-70
38. Dell'Omo G, Penno G, Pucci L, et al. The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coron Artery Dis 2005; 16 (1): 67-73
39. McCarty MF. Elevated sympathetic activity may promote insulin resistance syndrome by activating alpha-1 adrenergic receptors on adipocytes. Med Hypotheses 2004; 62 (5): 830-8
40. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9: 342-60
41. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-75
42. Krakoff LR. Comments on ALLHAT and doxazosin. Curr Control Trials Cardiovasc Med 2001; 2 (6): 254-6
43. Black HR. Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. J Cardiovasc Pharmacol 2003; 41 (6): 866-9